Background and objectives: Menopause is accompanied by higher prevalence of atherogenic lipid profiles, central obesity, and insulin resistance. Hepatic steatosis is frequent in postmenopausal women. Fetuin-A level is strongly related to liver fat content. Its role in menopausal metabolic derangements is largely unknown. We aimed to investigate the relation between fetuin-A and the development of menopausal metabolic complications related to obesity and if caloric restriction/estrogen supplementation could alleviate these abnormalities. Methods: Adult female Wistar rats were either bilaterally ovariectomized (OVX) (30 rats) or sham operated (sham group, n=10 rats). OVX rats were randomly subdivided into ovariectomized group (OVX), ovariectomized group treated with 17-β estradiol (OVX+E 2 ), and ovariectomized-caloric restricted group (OVX+CR) (n=10/group). Thirteen weeks following surgery, serum levels of glucose, insulin, lipids, fetuin-A and adiponectin were estimated. Weight of visceral fat and triacylglycerol (TAG) content of liver were assessed. Results: Serum fetuin-A level was increased following ovariectomy (113%, P<0.001). This was associated with increased visceral adiposity, abnormal lipid profile, insulin resistance, hypoadiponectinaemia and excessive accumulation of hepatic triacylglycerol (TAG). However, estrogen (E 2 ) supplementation/caloric restriction (CR) significantly suppressed elevated Fetuin-A (by 41.9%, P<0.001 and 31.2%, P<0.001, respectively). In addition, CR was equally effective as E 2 replacement in reversing metabolic abnormalities. Conclusion: Fetuin-A could be one of the factors contributing to the development of metabolic complications related to menopausal obesity. Caloric restriction alone can ameliorate those complications without the hazardous effects of estrogen replacement; possibly, through inhibition of serum fetuin-A level.
INTRODUCTION
Menopause is a time of great physical, psychological and biochemical changes for women. The decrease in estrogen levels in menopausal women is accompanied by alterations in energy homeostasis that result in loss of subcutaneous fat and an increase in visceral fat. [1] The increasing incidence of overweight and obesity in menopausal women is a public health concern.
[2] The reasons behind obesity in menopause are not fully understood. Some researchers refer it to the absence of estrogens.
[3]
Psychosocial factors may also contribute to menopausal obesity. However, the exact causes for obesity require further clarification.
Previous studies observed that daily food intake is increased in ovariectomized rats. [5, 6, 7] Menopausal women are at higher risks of metabolic dysfunction predisposing to cardiovascular diseases, type 2 diabetes mellitus (T2DM)), and metabolic syndrome. Higher prevalence of atherogenic lipid profiles, central obesity, hyperinsulinemia, and insulin resistance are common metabolic disorders. [8] Moreover, Nonalcoholic Fatty Liver Disease (NAFLD) is frequent in postmenopausal women.
[9]
Alterations in body composition, fat distribution and/or hormonal or metabolic changes that occur following menopause may influence the development and progression of NAFLD, [10] that ranges from simple steatosis to necroinflammation (steatohepatitis).
[11]
As ovariectomy enhances appetite, [4] the consequences of ovarian hormone deprivation in obesity and insulin resistance are aggravated by the effects of increased caloric intake. [12] However, the benefits of caloric restriction in ovariectomized rat model of menopause have not been fully determined.
Fetuin-A is an abundant serum protein produced predominantly in the liver. [13] Fetuin-A was originally described as a growth factor in fetal calf serum [14] and was later identified as an important inhibitor of ectopic calcification. [15] Among its pleotropic actions, fetuin-A was observed to inhibit autophosphorylation of insulin receptors through suppression of tyrosine kinase activity. [16] Thus, it may contribute to insulin resistance.
[17]
Furthermore, Fetuin-A was shown to induce the expression of some inflammatory cytokines associated with the metabolic syndrome and inhibit the expression of adiponectin, an adipokine with anti-inflammatory and insulin sensitizing actions. [18] While previous data have suggested a link between high fetuin-A levels and the metabolic syndrome, and reported a significant correlation between plasma levels of fetuin-A and liver fat content in subjects with increased risk of the metabolic syndrome, [19] the role of fetuin-A in menopausal metabolic derangements is largely unknown.
Taken together, the aim of this study was to investigate the hypothesis of fetuin-A being one of the factors contributing to the development of menopausal metabolic complications related to obesity. In addition, we aimed to explore whether those metabolic disorders can be simply prevented by CR and maintained body weight, or ERT is crucial in preventing them, with special concern to the impact of CR and ERT on fetuin-A level in surgically induced menopause in rats.
MATERIALS AND METHODS

Experimental animals
Adult female Wistar rats weighing 220-250 g at the beginning of the experiment were used. 
Surgery and ovariectomy
Rats were allowed to acclimatize for 1 week prior to surgery. Then, rats were anesthetized by intraperitoneal (ip) sodium thiopental (30 mg/kg) and both ovaries were removed according to previously described technique.
[20] Sham operated animals were subjected to same surgical procedure except that ovaries were gently manipulated but not excised. All rats were injected with gentamycin (5 mg/kg, ip) during surgery and then daily for one week. After surgery, rats were housed individually and observed for some hours to allow recovery and then re-grouped in their home cages.
Experimental groups
Rats in the experimental groups were either bilaterally ovariectomized (30 rats) or sham operated (sham group, n=10 rats). Following surgery, all rats were allowed to recover for one week. Then, OVX animals were randomly assigned into three groups (10 rats each): 
Estimation of body weight gain
All rats were weighed one week after surgery, before treatments supplementation, to determine baseline weights. Then, 12 weeks later, rats were weighed again to obtain end weight. Weight gain was calculated for each rat as the difference between the two weights. 
Sampling and biochemical analysis
Assessment of lipid profile
Serum total cholesterol (TC), and triglycerides (TG) were assayed using enzymatic colorimetric method. High density lipoprotein-cholesterol (HDL-C) was analyzed using NS Biotec HDLprecipitating reagent. Low density lipoproteincholesterol (LDL-C) was calculated using
Friedewald formula: LDL-C (mg/dl) = TC -HDL-C -(TG/5).
[24]
Weighing of visceral fat
Immediately after blood sampling, the abdominal cavity was opened; the perinephric, mesenteric, and retroperitoneal fat pads were removed and weighed. The sum of their weights was calculated as an indicator for visceral fat accumulation.
[25]
Estimation of liver triacylglycerol (TAG)
The liver was immediately removed, washed by iced phosphate buffered saline (PBS) and stored at 
RESULTS
Body weight gain and weight of visceral fat
Twelve weeks following ovariectomy, OVX group .001 versus OVX group. P value is calculated by least significant difference test.
Fig. 2.
Effect of 17B -estradiol administration and calorie restricted diet on (a) serum fetuin-A and (b) adiponectin levels in ovariectomized (OVX) rats. Data are represented as mean ± SEM of ten animals. Statistical differences were assessed by one-way ANOVA followed, when significant, by a least-significant-difference post-hoc test for pair-wise comparisons. * p<0.05, ** p<0.01, *** p<0.001 versus sham; # p<0.05, ## p<0.01, ###p<0.001 versus OVX group. P value is calculated by least significant difference test .001 Data are represented as mean ± SEM of 10 rats per group; OVX, ovariectomized; E 2 , 17 β-estradiol; CR, calorie restricted. HOMA-IR, homeostatic model assessment of insulin resistance index; C, cholesterol; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol. Statistical differences were assessed by one-way ANOVA followed, when significant, by a least-significant-difference post-hoc test for pair-wise comparisons. *P<0.05, **P<0.01, ***P≤0.001 versus sham, #P<0.05, ##P<0.01, ###P≤0.001versus OVX group. P value is calculated by least significant difference test. 3 . Effect of 17B -estradiol administration and calorie restricted diet on liver triacylglycerol (TAG) in ovariectomized (OVX) rats. Data are represented as mean ± SEM of ten animals. Statistical differences were assessed by one-way ANOVA followed, when significant, by a least-significant-difference post-hoc test for pair-wise comparisons. * p<0.05, ** p<0.01, *** p<0.001 versus sham; # p<0.05, ## p<0.01, ###p<0.001 versus OVX group. P value is calculated by least significant difference test. TAG, triacylglycerol; HOMA-IR, homeostatic model assessment of insulin resistance index; C, cholesterol; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; r, Pearson's correlation coefficient for pooled data (n=40).
DISCUSSION
Through the menopausal effects, women can increase total body fat content, favoring the central body fat distribution.
[27]
The reasons behind increasing abdominal obesity in menopausal women are not clear. Probably, estrogen deficiency is a major contributing factor.
Fetuin-A was previously implicated in insulin resistance and metabolic complications in different obesity-associated disorders.
[19] Therefore, it was noteworthy to investigate its possible role in ovariectomized rat model of menopause. visceral and hepatic tissues in overweight subjects. [33] This suggests that menopausal obesity could be simply prevented by caloric restriction Alterations in body composition, fat distribution and/or hormonal or metabolic changes that occur following menopause may influence the development and progression of NAFLD.
[10]
Estrogens-deficient state in ovariectomized animals has been repeatedly shown to result in a rapid liver fat accumulation. [34, 35, 36] the form of triglyceride-rich lipoprotein secretion. [37] Visceral fat, via its unique location and enhanced lipolytic activity, releases toxic-free fatty acids, which are delivered in high concentrations directly to the liver; therefore, excess intraabdominal fat deposition after estrogens withdrawal can primarily and partially explain hepatic fat accumulation. [38] Our results revealed that both caloric restriction and E 2 replacement were equivalent in decreasing liver TAG in comparison with OVX group. In line,
Rector et al. demonstrated that caloric restriction
can prevent the development of NAFLD in hyperphagic rats. [39] Nevertheless, Meyer et al.
observed that CR may be beneficial for reducing liver lipid and lowering triglycerides in overweight subjects without known NAFLD. [40] In a recent review, it was concluded that at present, there are no specific or effective pharmacological treatments available for NAFLD in older women, and lifestyle modifications with weight loss and exercise are regarded as first line treatments. [41] After menopause, risk of T2DM, atherosclerosis and coronary artery disease are more frequent, where insulin resistance and atherogenic lipid profile appear. [8, 42] Supporting these evidences, the current study confirmed development of insulin resistance thirteen weeks after ovariectomy. Additionally, we found a significant increase in the atherogenic lipid profile; TC, LDL-C and TG as well as a significant decline in the protective HDL-C in the OVX group compared to the sham controls.
Interestingly, both E 2 replacement and CR succeeded to ameliorate these metabolic derangements compared to the OVX rats;
decreased insulin resistance and almost normalized lipid profile. Yet, differences between E 2 and CR groups were insignificant. These findings are in accordance with previous researches demonstrated that caloric restriction can attenuate dyslipidaemia and/or improve insulin sensitivity in overweight people [40] and in streptozotocin induced diabetic rats. [43] Moreover, Stubbins et al. [44] proved that estrogen protected female mice from developing liver steatosis and insulin resistance.
Animal studies have consistently shown that fetuin-A knockout mice are resistant to weight gain and insulin resistance induced by high fat diet or aging. [17, 45] In addition, several human crosssectional studies documented a positive association between high fetuin-A level and prevalent diabetes. [46, 47] The present study an atherogenic lipid profile in humans. [19] In agreement to our results, plasma fetuin-A levels were positively correlated with fasting insulin and associated with higher risk of developing T2DM in USA women. [48] In the present study, a significant positive correlation was found between the level of fetuin-A and that of liver TAG. Similarly, Stefan et al.
found a significant correlation between plasma levels of fetuin-A and liver fat content in subjects with increased risk of the metabolic syndrome.
[49]
This highlights a possible increased fetuin-A secretion from the liver with increased TAG deposition after surgically induced menopause.
When hepatic steatosis was corrected by E 2 or CR, Adiponectin has been shown to have insulinsensitizing effects including; stimulation of fatty acid oxidation and glucose uptake in skeletal muscle and suppression of glucose production in the liver.
[51] Experimental studies suggested that administration of adiponectin ameliorates insulin resistance in T2DM mice.
[52] For those reasons, adiponectin is considered to be one of the major insulin-sensitizing hormones strongly involved in insulin resistance-related disorders.
Collectively, these studies suggest that the liversecreted protein, fetuin-A, inhibits generation of adiponectin in adipose tissue. Higher fetuin-A and lower adiponectin may contribute to obesityinduced insulin resistance.
[18]
In addition to its insulin sensitizing effects, our finding of improved lipid profile in the E 2 and CR groups could be attributed to higher adiponectin concentrations compared to the OVX group. In [54]
In summary, the probable mechanism of metabolic abnormality in obese menopausal female is with caloric excess, due to menopause induced hyperphagia, there is fatty acid excess fueling hepatic TAG synthesis and steatosis. Fatty liver may lead to greater serum fetuin-A concentrations.
Higher fetuin-A levels may be responsible for suppression of adiponectin secretion. Both 
